Literature Review

Chronic stress and genetics can raise the risk of Alzheimer’s disease


 

FROM BIOLOGICAL REVIEWS

Pay attention to stress

For clinicians, this paper highlights the importance of managing stress in patients and their families.

“Clinicians need to be attuned to the effects of stress on patients and their caregivers, and how that [stress] can affect their morbidity and mortality,” Cynthia Munro, PhD, associate professor of psychiatry and behavioral sciences at Johns Hopkins University, Baltimore, said in an interview. She added that attention must be paid to modifiable risk factors such as poor sleep and diet.

Cynthia Munro, PhD, associate professor of psychiatry and behavioral sciences, Johns Hopkins University, Baltimore

Dr. Cynthia Munro

Although managing stress is important, that doesn’t mean that everyone who’s experienced chronic stress will develop Alzheimer’s disease. “Chronic stress can alter the HPA axis but it doesn’t necessarily do so in everyone. A cascade of events needs to occur,” said Dr. Munro. “People should always try to reduce the effects of stress to the extent that they can. Stress can lead to a whole host of negative health outcomes, not just Alzheimer’s disease.”

Next steps

Moving forward, the researchers plan to further investigate the molecular mechanisms responsible for the role of stress in Alzheimer’s disease and how genetic variants affect neurodegeneration, Ms. Armstrong said. Ultimately, understanding how stress and genetics contribute to Alzheimer’s disease may lead to the identification of possible therapeutic targets.

Ms. Armstrong and Dr. Munro declared no relevant financial relationships. The study was independently funded.

Pages

Recommended Reading

Cannabinoids promising for improving appetite, behavior in dementia
Federal Practitioner
Age-related cognitive decline not inevitable?
Federal Practitioner
Are psychiatric disorders a ‘canary in a coal mine’ for Alzheimer’s disease?
Federal Practitioner
When to refer patients with new memory loss
Federal Practitioner
The end of happy hour? No safe level of alcohol for the brain
Federal Practitioner
FDA approves controversial Alzheimer’s drug aducanumab (Aduhelm)
Federal Practitioner
The aducanumab revolution
Federal Practitioner
Watchdog group demands removal of FDA leaders after aducanumab approval
Federal Practitioner
Is trouble falling asleep a modifiable risk factor for dementia?
Federal Practitioner
Hearing loss tied to decline in physical functioning
Federal Practitioner